Perrigo to review options for Multiple Sclerosis drug Tysabri

(Reuters) - Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news